Sign In
1 May 2019 08:05
Yourgene Health plc
("Yourgene" or the "Company")
Total Voting Rights
Manchester, UK - 1 May 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces that the Consideration Shares have today been admitted to trading on AIM and total voting rights are 598,999,688 after full completion of all aspects of the Fundraise and the Acquisition in the announcement dated 17 April 2019.
The Company's issued share capital as at the date and time of this announcement consist of 598,999,688 ordinary shares of 0.1 pence each ('Ordinary Shares'). There are no Ordinary Shares held in treasury.
Accordingly, the total number of voting rights in Yourgene Health plc at the date of this notice is 598,999,688.
The above figure of 598,999,688 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Capitalised terms used but not defined in this announcement have the same meanings as defined in the Company's announcement released on 17 April 2019, detailing the proposed acquisition by the Company of Elucigene.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For more information, please contact:
| |
Yourgene Health plc Lyn Rees, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing investors@yourgene-health.com
| Tel: +44 (0)161 667 1053
|
Cairn Financial Advisers LLP (Nomad) Liam Murray / James Caithie / Ludovico Lazzaretti
| Tel: +44 (0)20 7213 0880 |
Stifel Nicolaus Europe Limited (Broker) Nicholas Moore / Matthew Blawat / Ben Maddison
| Tel: +44 (0)20 7710 7600 |
Vigo Communications (PR) Ben Simons / Fiona Henson / Antonia Pollock yourgene@vigocomms.com | Tel: +44 (0)20 7390 0238
|
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions.
Yourgene Health's first commercialised products are NIPT for Down's Syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market.
Prenatal screening is an established clinical practice, but accuracy challenges with traditional methods are driving the need for NIPT and other DNA-based reproductive health testing solutions. Our commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Through our technical expertise and partnerships, Yourgene Health is aiming to extend its genetic testing offering into complementary areas of reproductive health and oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
Follow the stocks
